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Abstract: The molecular etiology of keratoconus (KC), a pathological condition of the human
cornea, remains unclear. The aim of this work was to perform profiling of metabolites and
identification of features discriminating this pathology from the normal cornea. The combination
of gas chromatography and mass spectrometry (GC/MS) techniques has been applied for profiling
and identification of metabolites in corneal buttons from 6 healthy controls and 7 KC patients.
An untargeted GC/MS-based approach allowed the detection of 377 compounds, including 46
identified unique metabolites, whose levels enabled the separation of compared groups of samples
in unsupervised hierarchical cluster analysis. There were 13 identified metabolites whose levels
differentiated between groups of samples. Downregulation of several carboxylic acids, fatty acids,
and steroids was observed in KC when compared to the normal cornea. Metabolic pathways
associated with compounds that discriminated both groups were involved in energy production,
lipid metabolism, and amino acid metabolism. An observed signature may reflect cellular processes
involved in the development of KC pathology, including oxidative stress and inflammation.
Keywords: keratoconus; cornea; ocular metabolomics; GC/MS profiling
1. Introduction
Keratoconus (KC) is among the most common indications for corneal transplantation [1–3]. This is
an eye ectatic disorder characterized by the progressive corneal thinning, protrusion, and irregular
myopic astigmatism, which in advanced cases can lead to severe visual distortions. KC is a serious
clinical problem worldwide. The prevalence of the disease in the general population is estimated at
50 to 250 cases per 100,000 individuals [4,5], and even higher in some regions of Asia [6,7]. KC is
primarily diagnosed in youths and young adults, hence it is the most common indication for corneal
transplantation in people under 40 years of age [2,3,8]. Despite a great deal of research, the pathogenesis
of KC is still poorly understood. Most likely, the condition results from the interaction of multiple
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factors including genetic and environmental ones. Among proven intrinsic mechanisms involved in
etiology of KC, there are alterations in enzymes activity (e.g., lysyl oxidase, matrix metalloproteinases)
that, by attenuation of covalent bonds between collagen fibrils and disorganization of the extracellular
matrix, can lead to deterioration of biomechanical and optical properties of the cornea [9–11]. What is
more, several reports are showing that corneal components involved in protection against oxidative
stress damage are changed in this disorder. The increased levels of oxidative stress markers and the
decreased antioxidant defenses in KC corneas can indicate that oxidative stress might be involved in
the development of this pathology [9,12–16].
Recent studies point to the metabolic changes as a key to understand the pathogenesis of eye
diseases [17–19]. The pathologic processes occurring in corneal tissue can be reflected in the metabolome
changes, causing the increase or decrease of particular metabolites [20]. Metabolomic indicators of
oxidative stress, such as glutathione, are considered as one of the major factors involved in the
development of corneal diseases [21]. Furthermore, changes in the lipid composition of eye tissue
can be responsible for the modulation of responses to inflammation and oxidative stress occurring in
ophthalmic pathologies [22].
Despite the growing number of translational and laboratory studies proving the role of oxidative
stress and inflammation in KC, it should be emphasized that probably not all forms of KC can be
definitively linked to inflammatory metabolites [23]. Inflammation alone is clearly not sufficient to
induce KC, because many patients with severe keratitis do not develop KC. Another inconsistency
that is pointed out is the lack of histological and clinical features of inflammation, such as cell
infiltration and neovascularization in keratoconic corneas [24]. The complex interactions between
genetic predisposition to abnormalities of any of inflammatory components and environmental triggers
(eye rubbing, wearing contact lenses, or exposure to ultraviolet light) are likely to be the key to
understanding the role of inflammatory mediators and its diverse contribution in the development of
various subtly different phenotypes of KC [25,26].
In recent years several groups have investigated the metabolome composition of keratoconic
cornea tissue [27] as well as the aqueous humor [28] and tear film of KC patients [20]. The metabolome
composition of the human cornea has been studied with the use of different NMR spectroscopy
techniques, including 31P NMR [29] and HR-MAS 1H NMR [27]. Mass spectrometry methods,
mainly coupled to liquid chromatography (LC/MS), were applied for metabolomics studies of the
human lens [30], tear fluid [21], or aqueous humor [20]. However, the knowledge of the metabolome
composition of the human cornea in specific pathogenic conditions remains very limited. Moreover,
there are some limitations of above mentioned analytical technics, including low sensitivity of NMR
and narrowing of LC/MS analytical capabilities only to polar compounds. In the present study, the
combination of gas chromatography and mass spectrometry (the GC/MS approach) has been applied
for the first time to the profiling of the metabolome of keratoconus, which reveals metabolomics
signature discriminating this pathology and the healthy human cornea.
2. Methods
2.1. Ethics Statement
The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the
Bioethical Committee of the Maria Skłodowska-Curie Institute—Oncology Center, Branch Gliwice,
Poland (permit number KB/430-01/14). Written informed consent was obtained from all patients.
2.2. Tissue Collection
Seven corneal buttons 7.5–8.25 mm in diameter derived from patients who underwent penetrating
corneal transplantation due to keratoconus (KC) were used for the analysis. Six normal cornea samples
from the donor material not suitable for transplantation were obtained from the Eye Tissue and Cells
Bank, St. Barbara Hospital, Sosnowiec, Poland, and used as healthy controls (HC). Corneal buttons
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trephined from normal corneas were fully transparent and 8.0 mm in diameter. Because altered lipid
retention was reported in diabetic corneas [31], patients with an abnormal lipogram and patients with
diabetes were excluded from the study. Moreover, to eliminate possible age-related differences we
included samples derived from individuals with a similar age in both groups: KC patients aged 42 to
59 years and HC donors aged 40 to 69 years. All surgeries were performed in the Clinical Department
of Ophthalmology, Railway Hospital in Katowice, Poland. All KC eyes included in the study were
in an advanced stage of the disease, with high refractive errors and severe loss of visual acuity, but
no scarring or a history of acute hydrops. Healthy corneas were stored in a synthetic corneal storage
medium (Eusol-C, Alchimia, Padova, Italy) for 5 to 8 days before they were qualified as not suitable for
transplantation and used for analyses. Therefore, immediately after excision KC buttons were placed
in Eusol-C for seven days before further preparation.
2.3. Sample Processing and Metabolite Extraction
The buttons were rinsed twice in PBS and fixed in buffered formalin (3.7% formaldehyde in
10 mM phosphate buffer, pH 7.4) for 24 h at room temperature, then frozen and stored at −80 ◦C until
analysis. The frozen tissue samples were ground in liquid nitrogen in precooled adaptors for 45 s at
30 Hz frequency using a ball mill MM400 (Retsch, Germany). Pulverized tissue was homogenized
in 250 µL mixture of 80% MeOH using a vortex mixer for 5 min and placed in an ultrasonic bath for
10 min. The resulting mixture was centrifuged for 10 min at 23,000× g in 4 ◦C. The supernatant was
transferred to a new tube (polar fraction) and the pellet was suspended in 250 µL of a mixture of
CH2Cl2:MeOH (3:1 v/v) and processed as described above to generate the non-polar fraction. Both
polar and non-polar fractions were combined, transferred to a new tube and evaporated in a SpeedVac
concentrator. The dried extract was then derivatized with 25 µL of methoxyamine hydrochloride in
pyridine (20 mg/mL) at 37 ◦C for 90 min with agitation. The second step of derivatization was performed
by adding 40 µL of N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) and incubation at 37 ◦C
for 30 min with agitation. Samples were subjected to GC/MS analysis directly after derivatization.
2.4. GC/MS Analysis
The GS/MS analysis was performed using an Agilent 7890A gas chromatograph
(Agilent Technologies) connected to a Pegasus 4D GCxGC-TOFMS mass spectrometer (Leco). A DB-5
bonded-phase fused-silica capillary column (30 m length, 0.25 mm inner diameter, 0.25 µm film
thickness) (J&W Scientific Co., Folsom, CA, USA) was used for separation. The GC oven temperature
program was as follows: 2 min at 70 ◦C, raised by 8 ◦C/min to 300 ◦C and held for 16 min at 300 ◦C.
The total time of the GC analysis was 46.75 min. Helium was used as the carrier gas at a flow rate
of 1 mL/min. One microliter of each sample was injected in the splitless mode. The initial injector
temperature was 20 ◦C for 0.1 min and after that time raised by 600 ◦C/min to 350 ◦C. The septum
purge flow rate was 3 mL/min and the purge was turned on after 60 s. The transfer line and ion source
temperatures were set to 250 ◦C. In-source fragmentation was performed with 70 eV energy. Mass
spectra were recorded in the mass range 35–650 m/z.
2.5. Analysis of Spectral Data
Data acquisition, automatic peak detection, mass spectrum deconvolution, retention index
calculation, and library search were done by the Leco ChromaTOF-GC software (v4.51.6.0). To eliminate
retention time (Rt) shift and to determine the retention indexes (RI) for each compound, the alkane
series mixture (C-10 to C-36) was injected into the GC/MS system. The metabolites were automatically
identified by library search (Replib, Mainlib, Fiehn library); the analyte was considered as identified
when it passed the quality threshold: Similarity index (SI) above 700 and matching retention index
±10. Identified artifacts (alkanes, column bleed, plasticizers, MSTFA, and other used reagents) were
excluded from further analyses. To obtain accurate peak areas for the deconvoluted components,
unique quantification masses for each component were specified and the samples were reprocessed.
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The obtained profiles were normalized against the sum of the chromatographic peak area (using the
total ion chromatograph (TIC) approach—relative quantification).
2.6. Statistical and Chemometric Analyses
Quantitative analysis was performed for metabolites identified in at least 60% of samples in
each group; the nearest neighbor method was used for missing data imputation. The data were
log-transformed. Differences in the abundances of metabolites among two groups were tested
using the t-test, Welch test, or Mann–Whitney U test, depending on the normality distribution and
homoscedasticity of the analyzed data. The results were presented in arbitrary units as mean abundance
after normalization and transformation. Principal Component Analysis (PCA) and hierarchical cluster
analysis (HCA) based on the Euclidean distance method were performed to illustrate similarities
between samples. All statistical calculations and multivariate data analyses were performed using the
Perseus software (http://www.coxdocs.org/doku.php?id=perseus:start). Metabolomic pathways were
identified using the Metabolite Set Enrichment Analysis (MSEA) (http://www.msea.ca/MSEA/faces/
Home.jsp), which is the metabolomic version of the Gene Set Enrichment Analysis (GSEA) approach.
A list of selected metabolites was used as an input for the Over-Representation Analysis (ORA)
algorithm, which was implemented using the hypergeometric test to evaluate the over-representation
of a particular metabolite set; fold-enrichment values and one-tailed p-values corrected for multiple
testing were provided.
3. Results
The metabolome profiling was performed for 7 samples of keratoconus (KC) and 6 samples of
the healthy cornea (healthy controls—HC) using the GC/MS technique. To the best of our knowledge,
this is the first application of GC/MS-based protocol (adapted from Wojakowska et al. [32]) in the
profiling of metabolites from human corneal buttons. In general, there were 46 unique metabolites
identified and quantitated in analyzed samples, which included amino acids, carboxylic acids, fatty
acids and their esters, sugars and sugar alcohols, sterols and others (the complete list of identified
compounds is presented in Supplementary Table S1). Moreover, there were 331 compounds (analytes)
detected that could not be identified with the implemented approach. All detected metabolites (both
identified compounds and unidentified analytes) were used to perform an unsupervised comparison
of samples from both groups. The principal component analysis showed some clustering of samples
from both groups, which resulted in the separation of KC and HC samples (Figure 1A). Similarly,
the hierarchical cluster analysis also showed the clustering of samples and separation of both groups
(Figure 1B). This result indicated the presence of metabolites with abundances significantly different
between HC and KC samples, which was further analyzed using supervised tools.
There were 13 identified metabolites whose levels differed significantly (p < 0.05) between both
types of the cornea (Table 1). In general, 3 carboxylic acids (namely benzoic, glycolic, and succinic) and
6 fatty acids (namely linoleic, myristic, palmitic, pentadecanoic, stearic, and trans-13-octadecenoic) were
downregulated in keratoconus. Similarly, cholesterol, cholesta-3,5-diene (2 isomers) and hexadecanol
were downregulated in the pathological cornea. On the other hand, phosphoric acid was upregulated
in KC. Moreover, there were 3 metabolites detected only in one group of samples: gluconic acid and
cholesterol propionate were absent in HC samples while petroselenic acid was absent in KC samples
(Table 1).
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Figure 1. Separation of normal (HC) and keratoconus (KC) samples of human cornea samples by the
principal component analysis (A) and hierarchical cluster analysis (B).
Table 1. Metabolites that differentiate the healthy cornea (HC) from keratoconus (KC).
Metabolite Name Class HC
Mean Abundance
KC
Mean Abundance
HC/KC
FC p-Value
Benzoic acid Carboxylic acids 180 119 1.51 0.0338
Glycolic acid Carboxylic acids 6.18 2.65 2.33 0.0258
Succinic acid Carboxylic a ids 771 536 1.44 0.0096
Gluconic acid Carboxylic acid N.D. 0.56 - -
Linoleic acid Fatty acids 103 38.8 2.65 0.0144
Myristic acid Fatty acids 175 112 1.56 0.0197
Palmitic acid Fatty acids 7240 4250 1.70 0.0042
Pentadecanoic acid Fatty acids 122 74.3 1.64 0.0163
Stearic acid Fatty acids 7440 4810 1.55 0.0159
trans-13-Octadecenoic acid Fatty acids 149 83.3 1.79 <0.0001
Petroselinic acid Fatty acids 256 N.D. - -
Cholesta-3,5-diene—isomer 1 Sterols 83.6 17.6 4.75 0.0032
Cholesta-3,5-diene—isomer 2 Sterols 421 85.5 4.92 0.0016
Cholesterol Sterols 5680 1960 2.90 0.0218
Cholesterol propionate Sterol esters N.D. 0.12 - -
Hexadecanol Alcohols 109 76.3 1.43 0.0147
Phosphoric acid Others 56,900 67,700 0.84 0.0228
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In the next step, 13 metabolites indexed in the Human Metabolome Database (HMDB) that
showed significantly different abundances between keratoconus and healthy cornea were subjected
to the metabolite set enrichment analysis, which allowed to identify metabolic pathways associated
with these discriminatory compounds (Figure 2 shows the top 20 of such pathways). We found that
metabolic pathways associated with compounds showing different abundances between HC and KC
samples included processes connected with energy production (Warburg effect, tricarboxylic acid
cycle, ketone body metabolism, and mitochondrial electron transport chain) and lipid metabolism
(fatty acid, glycerolipids and steroid biosynthesis, carnitine synthesis). Moreover, pathways involved
in the metabolism of amino acids (Arg, Pro, Val, Leu, Ile, and Glu metabolism) were over-represented
among processes associated with compounds that discriminated against different states of the cornea.
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Figure 2. Metabolic pathways associated with 13 metabolites showing significantly different abundances
between keratoconus and healthy cornea. Presented are over-representation (fold enrichment) and
its statistical significance (uncorrected p-value) of metabolic pathway estimated by the metabolite set
enrichment analysis (MSEA); the top 20 pathways are represented.
4. Discussion
Until now, only a few studies concerning metabolome profiling of human cornea have been
reported. The molecular composition of this tissue was analyzed using NMR spectroscopy by groups
of Greiner [29,33] and Kryczka [16,34,35], yet the number of identified and quantified compounds was
rather low due to the limitations of this approach, which is less sensitive than MS and needs more
amount of sample for analysis. Moreover, due to the limited availability of corneal tissue for research,
many recent LC/MS-based studies on the cornea metabolism and the differences between healthy and
keratoconus cornea have been necessarily carried out based on the analysis of tears [21,36], aqueous
humor [20], saliva [37] and cell lines [22,38]. In this work, the GC/MS approach was introduced for the
first time to the metabolomics profiling of human cornea using corneal buttons. GC/MS-based approach
including derivatization of the sample allows analysis of a wide range of compounds (polar and
nonpolar). However, the strength of our study is directly related to its limitations, which is the small
number of samples tested.
Major classes of detected metabolites were fatty acids, sterols (cholesterol derivatives) and
their esters, carboxylic acids (e.g., citric, succinic, and oxalic acids) as well as sugars and their
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derivatives (glucose, gluconic acid, sorbitol, and myo-inositol). Moreover, because of the limitations
of untargeted profiling implemented in the current study, a large number of detected compounds
remained unidentified, a problem frequently reported in this type of study [36]. It is worth noting that
several unidentified compounds also showed significantly different abundances between samples of
the healthy and pathological cornea. Therefore, differences in the molecular composition of these two
cornea conditions might be further studied using alternative metabolomics approaches.
The crucial problem in analogous studies is to distinguish the differences in metabolite composition
between the normal and diseased tissue from those resulting from post-mortem chemical processes.
All normal cornea samples used in our study derived from corneal buttons were harvested up to 3 h
after death. This is due to the Eye Bank procedure, according to which the corneas are obtained either
at the time of multi organ donation, or soon after two hours have passed since death, in hospital setup.
Such an early harvesting time allowed to exclude post-mortem metabolic changes, especially since
they proceed very slowly compared to those occurring in the blood or even in the aqueous humor [20].
The molecular pathogenesis of keratoconus is poorly understood. However, it has been suggested
that oxidative stress and lipid peroxidation may be involved in this pathological state of the cornea [16].
Oxidative stress in the cornea stimulates the generation of pro-inflammatory cytokines, proteolytic
enzymes, and enzymes responsible for the generation of nitric oxide. Accumulation of reactive oxygen
species (ROS) and nitric oxide can lead to cell membrane damage by lipid peroxidation and release
of cytotoxic aldehydes [10]. Immunohistochemical studies by Buddi et al. revealed the presence
of markers of oxidative stress (nitrotyrosine) and lipid peroxidation (malondialdehyde) as well as
the expression of endothelial nitric oxide synthase in KC cornea [13]. Moreover, studies revealed
changes in the antioxidant status of KC and reported metabolites that are indicators of response to
oxidative stress (e.g., glutathione) [10,28,39]. Furthermore, alteration of phosphate metabolism [29]
and metabolites associated with the tricarboxylic acid cycle or the Krebs cycle (TCA) and urea cycle [21]
were also reported in KC patients.
Here we revealed a few metabolites whose patterns discriminated normal healthy cornea from
keratoconus, which included certain carboxylic acids, fatty acids, and sterols markedly downregulated
in the pathological state of the tissue. Fatty acids downregulated in KC included saturated (stearic,
palmitic, myristic, and pentadecanoic acid) and unsaturated (linoleic and trans-13-octadecenoic acid)
compounds. The fatty acids predominantly present within the human cornea are oleic, palmitic, and
stearic acids [40]. Lipids (along with fatty acids) constitute one of the main components of human
cornea and play important roles in complex processes associated with pro- and anti-inflammatory
reactions as well as tissue damage and repair. They can act as second messengers for an epidermal
growth factor (e.g., lipoxygenase (LOX) derivatives from arachidonic acid) to promote the proliferation
and repair of corneal tissue or as mediators of platelet-activating factor (PAF) and cyclooxygenase-2
(COX2) that contribute to tissue damage and neovascularization [41]. Linoleic acid is involved in
the biosynthesis of arachidonic acid and prostaglandins (PGs), as well as thromboxane (TXAs) and
lipoxygenase (LOX) derivatives, whose levels increase after corneal injury [42]. Moreover, recent
studies revealed that polyunsaturated fatty acids (PUFAs), including linoleic acid, play an important
role in the reparative processes of the cornea due to their anti-inflammatory effects [43]. Carboxylic
acids are another group of compounds discriminating KC and normal cornea. Gluconic acid, here
detected exclusively in KC samples, is an intermediate in the pentose phosphate pathway (PPP),
essential for the production of NADPH required for the synthesis of fatty acids and lipids [44]. Recent
studies showed that dysregulation of the pentose phosphate pathway metabolites, including gluconic
acid, in diabetic retinopathy (DR) provided further links to oxidative stress. Therefore, gluconic acid,
as a product of glucose oxidation, could be an indicator of oxidative stress in KC. On the other hand,
downregulation of succinic acid was observed in KC. Succinic acid plays an important role in TCA
(tricarboxylic acid) cycle, the dysregulation of which is associated with changes in energy requirements.
In the cornea, the TCA cycle is the key source of energy required to maintain corneal transparency and
cellular activity [45]. Under the healthy state, the TCA cycle is relatively quiet; however, it becomes
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activated upon injury. Recent studies revealed that succinic acid alterations are associated with various
retinal diseases [18] and TCA metabolites are highly altered in KC patients [21].
In general, metabolites whose levels differentiated normal and pathological cornea were associated
with the production of energy and lipid metabolism. Moreover, identified metabolites were associated
with response to oxidative stress, inflammation, and tissue damage. Hence, our observation confirmed
previous reports that suggested the role of oxidative stress and pro-inflammatory processes in the
development of keratoconus [21,37,38,46].
5. Conclusions
The presented work is the first application of the GC/MS-based metabolomic profiling that
demonstrated differences in metabolite composition between the keratoconus and normal human
cornea. The obtained metabolomic signatures indicate that oxidative stress and inflammatory reactions
are involved in the development of this corneal pathology. However, further in-depth metabolomics
study that will address a complete ocular metabolome is required to decipher the key metabolic
changes crucial for the etiopathology of the keratoconus.
Supplementary Materials: The following are available online, Table S1: Metabolites identified and quantified by
GC/MS in keratoconus (KC) and healthy cornea (HC) samples.
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